EICHORPublic-registry trials using Bendamustine that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
| Trial | Sponsor | Condition | Phase | Sites |
| Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma | TG Therapeutics, Inc. | Diffuse Large B-Cell Lymphoma | PHASE2 / PHASE3 | 168 |
| First FDA approval | TREANDA — March 2008 (application NDA022249, currently held by CEPHALON) |
| Approval timeline | TREANDA 2008 (CEPHALON) → BENDEKA 2015 (EAGLE PHARMS) → BELRAPZO 2018 (EAGLE PHARMS) → BENDAMUSTINE HYDROCHLORIDE 2022 (DR REDDYS) → VIVIMUSTA 2022 (AZURITY) |
| Also known as | TREANDA · BENDEKA · BELRAPZO · BENDAMUSTINE HYDROCHLORIDE · VIVIMUSTA |
| Approved applications | 17 — a multi-source (generic) drug |
| Forms & routes | Powder, Solution, Injectable · Intravenous, Injection |
| Registry-wide use | 452 registered studies all-time · 56 currently recruiting |
Sources: FDA Drugs@FDA and ClinicalTrials.gov, public records. The application holder shown is the current holder, which may differ from the original developer.
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Trialed alongside
Other Diffuse Large B-Cell Lymphoma drugs
← Eichor home · All tracked trials · Diffuse Large B-Cell Lymphoma studies · Weekly briefs
